세계의 암 바이오마커 시장 예측(-2029년) : 프로파일링 기술별, 암 유형별, 제품별, 용도별, 최종사용자별, 지역별
Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2029
상품코드:1473750
리서치사:MarketsandMarkets
발행일:2024년 04월
페이지 정보:영문 339 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 암 바이오마커 시장 규모는 2024년 245억 달러에서 2029년에는 420억 달러에 달할 것으로 예측되며, 예측 기간 중 CAGR은 11.3%에 달할 것으로 보이고 있습니다.
암 바이오마커 창출에서 기술의 급속한 향상 및 암이환율의 세계 상승 등의 요인이 시장 확대를 지원하고 있습니다. 그러나 이 시장 확대의 주요 장애는 암 바이오마커 검증의 어려움과 유자격자의 부족입니다.
조사 범위
조사 대상년
2022-2029년
기준년
2023년
예측 기간
2024-2029년
검토 단위
금액(10억 달러)
부문
프로파일링 기술별, 암 유형별, 제품별, 용도별, 최종사용자별, 지역별
대상 지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC 국가
암 바이오마커 시장은 프로파일링 기법에 따라 오믹스 기술과 이미징 기술의 두 가지 부문으로 나뉘며, 2023년까지 연평균 성장률(CAGR)이 가장 높은 부문은 오믹스 기술입니다. 이는 프로테오믹스 및 유전체학이 약물 개발, 신약 개발, 암 진단 개선 등에 활용되고 있기 때문입니다.
2023년 암 바이오마커 시장에서 유방암 카테고리가 가장 빠른 성장률을 보였습니다. 기술 발전과 전 세계 암 유병률 증가 및 암 바이오마커의 개발은 이 부문의 성장을 가속하는 두 가지 중요한 측면입니다.
용도별로는 연구개발 분야가 2020년 가장 높은 CAGR을 나타낼 것으로 예상됩니다. 이는 암 바이오마커 연구개발 증가와 신약개발에서 암 바이오마커의 적용이 확대되고 있기 때문입니다.
최종사용자별로 보면 2023년 진단 실험실 부문이 암 바이오마커 시장에서 더 큰 점유율을 차지할 것으로 예상됩니다. 암 바이오마커 기반 진단 검사를 수행하는 임상 실험실의 수가 전 세계에서 증가하고 있으며, 악성 종양의 유병률이 증가함에 따라 이 최종사용자 부문이 큰 비중을 차지하게된 것으로 분석됩니다.
세계의 암 바이오마커 시장에 대해 조사했으며, 프로파일링 기술별, 암 유형별, 제품별, 용도별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
서론
시장 역학
가격 분석
특허 분석
밸류체인 분석
공급망 분석
암 바이오마커 시장의 에코시스템 분석
Porter's Five Forces 분석
규제 분석
무역 분석
진단 및 검사 시약 무역 분석
기술 분석
주요 기술
보완 기술
인접 기술
2024-2025년의 주요 컨퍼런스와 이벤트
고객의 비즈니스에 영향을 미치는 동향/혼란
주요 이해관계자와 구입 기준
사례 연구 분석
투자와 자금조달 시나리오
제6장 암 바이오마커 시장, 프로파일링 기술별
서론
오믹스 기술
이미징 기술
제7장 암 바이오마커 시장, 암 유형별
서론
유방암
폐암
대장암
전립선암
흑색종
백혈병
갑상선암
방광암
비호지킨림프종
신장암
기타
제8장 암 바이오마커 시장, 제품별
서론
기기
소모품
바이오인포매틱스 소프트웨어
제9장 암 바이오마커 시장, 용도별
서론
진단
연구개발
예후
리스크 평가
기타
제10장 암 바이오마커 시장, 최종사용자별
서론
진단 검사실
바이오의약품 기업과 CRO
연구·학술기관
기타
제11장 암 바이오마커 시장, 지역별
서론
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
GCC 국가
제12장 경쟁 구도
개요
주요 참여 기업이 채택한 비책
매출 분배 분석
시장 점유율 분석
기업 평가 매트릭스 : 주요 참여 기업
경쟁 평가 매트릭스 : 스타트업/중소기업(2023)
암 바이오마커 벤더의 평가와 재무 지표
브랜드/제품 비교 분석
경쟁 시나리오
제13장 기업 개요
주요 참여 기업
F. HOFFMANN-LA ROCHE LTD.
THERMO FISHER SCIENTIFIC INC.
QIAGEN
BIO-RAD LABORATORIES, INC.
ILLUMINA, INC.
AGILENT TECHNOLOGIES, INC.
ABBOTT LABORATORIES
BIOMERIEUX
MERCK KGAA
BECTON, DICKINSON AND COMPANY
기타 기업
MYRIAD GENETICS, INC.
SYSMEX CORPORATION
HOLOGIC, INC.
QUEST DIAGNOSTICS
CENTOGENE N.V.
BIOGENEX
SIEMENS HEALTHINEERS
EXACT SCIENCES
R&D SYSTEMS, INC.
BIOVISION INC.
OLINK
ASURAGEN, INC.
MESO SCALE DIAGNOSTICS, LLC
INVIVOSCRIBE, INC.
INOVIQ LTD.
제14장 부록
KSA
영문 목차
영문목차
The global cancer biomarkers market is projected to reach USD 42.0 billion by 2029 from USD 24.5 billion in 2024, at a CAGR of 11.3% during the forecast period. Factors like the rapid improvements in technology propel market expansion. in the creation of cancer biomarkers and the global rise in cancer incidence. However, the main obstacles to this market's expansion are the difficulties in validating cancer biomarkers and the lack of qualified workers.
Scope of the Report
Years Considered for the Study
2022-2029
Base Year
2023
Forecast Period
2024-2029
Units Considered
Value (USD) Billion
Segments
Profiling technology, cancer type, product type, application, end-user, and region
Regions covered
North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries
"Omics technologies segment accounted for the highest CAGR"
The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2023. This is explained by the growing use of proteomics and genomics in medication development and discovery as well as improved cancer diagnostics.
"The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period"
The market for cancer biomarkers is divided into categories according on the kind of cancer, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, and other cancer types. In the market for cancer biomarkers in 2023, the breast cancer category had the fastest growth rate. increasing progress in technology The increasing global prevalence of cancer and the development of cancer biomarkers are two important aspects driving this segment's growth.
"Diagnostics segment accounted for the highest share"
The market for cancer biomarkers has been divided into segments based on application, including risk assessment, prognostics, diagnostics, and research & development. 2020 had the highest CAGR in the research and development sector. This can be linked to the rise in cancer biomarker research and development as well as the growing application of cancer biomarkers in medication discovery and development.
"Diagnostic Laboratories segment accounted for the highest share"
Based on end user, the cancer biomarker market is segmented into diagnostic laboratories, Biopharmaceutical Companies & CROs, research and academic institutes and other end-users. In 2023, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. he expanding number of clinical laboratories performing cancer biomarker-based diagnostics tests worldwide and the rising prevalence of malignancies are responsible for this end-user segment's sizeable share.
"Asia Pacific: The fastest-growing region in cancer biomarkers market"
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Rising technological advancements In the development of cancer biomarkers and increasing incidence of cancer worldwide are driving the growth of the cancer biomarkers market in this region.
Breakdown of supply-side primary interviews, by company type, designation, and region:
By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
By Designation: C-level (27%), Director-level (18%), and Others (55%)
By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)
Lists of Companies Profiled in the Cancer Biomarkers Market Report:
F. Hoffmann-La Roche Ltd. (Switzerland)
Thermo Fisher Scientific, Inc. (US)
QIAGEN N.V. (Netherlands)
Illumina, Inc. (US)
Bio-Rad Laboratories, Inc. (US)
Abbott Laboratories (US)
bioMerieux SA (US)
Becton, Dickinson and Company (US)
Merck Millipore (US)
Agilent Technologies (US)
Myriad Genetics, Inc. (US)
Sysmex Corporation (Japan)
Hologic, Inc. (US)
Quest Diagnostics (US)
Centogene N.V. (Germany)
BioGenex (India),
Siemens Healthineers (Germany)
Exact Sciences (US)
R&D Systems, Inc. (US)
BioVision, Inc. (US)
Olink (Sweden)
Asuragen, Inc. (US)
Meso Scale Diagnostics, LLC (US)
Invivoscribe, Inc. (US)
INOVIQ Ltd. (Australia)
Research Coverage
This research report categorizes the cancer biomarker market by profiling technology, cancer type, product type, application, enduser, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the Surface disinfectant market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarker market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
Analysis of key drivers (High prevalence of cancer, growing use for research and diagnosis), restraints (Technical issues related to sample collection and storage), opportunities (Rising healthcare expenditure, Increasing Demand from Emerging Economies), and challenges (lack of skilled professionals) influencing the growth of the cancer biomarker market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cancer biomarker market
Market Development: Comprehensive information about lucrative markets - the report analyses the cancer biomarker market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer biomarker market
Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), among others in cancer biomarker market.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
FIGURE 2 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 3 CANCER BIOMARKERS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 8 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
2.7.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 10 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 11 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 12 CANCER BIOMARKERS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 CANCER BIOMARKERS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 CANCER BIOMARKERS MARKET OVERVIEW
FIGURE 16 TECHNOLOGICAL ADVANCEMENTS IN CANCER BIOMARKERS TO DRIVE MARKET
4.2 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2024 VS. 2029
FIGURE 17 OMICS TECHNOLOGIES TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2024 VS. 2029
FIGURE 18 LUNG CANCER SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2029
4.4 CANCER BIOMARKERS MARKET SHARE, BY PRODUCT, 2024 VS. 2029
FIGURE 19 INSTRUMENTS SEGMENT TO DOMINATE CANCER BIOMARKERS MARKET IN 2024
4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2024 VS. 2029
FIGURE 20 DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2029
4.6 CANCER BIOMARKERS MARKET SHARE, BY END USER, 2024 VS. 2029
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements in cancer biomarkers
5.2.1.2 Increasing incidence of cancer
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015-2035
5.2.1.3 Rising use of cancer biomarkers in drug discovery & development
5.2.1.4 Increasing R&D on cancer biomarkers
5.2.2 RESTRAINTS
5.2.2.1 Technical issues related to sample collection and storage
5.2.2.2 High capital investments and extensive timelines for development of cancer biomarkers
TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS
5.2.2.3 Unfavorable regulatory and reimbursement scenarios
5.2.3 OPPORTUNITIES
5.2.3.1 Personalized medicine
FIGURE 24 WORKFLOW FOR PERSONALIZED TREATMENT
FIGURE 25 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS
5.2.3.2 Growing applications of companion diagnostics
TABLE 5 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
5.2.3.3 Emerging economies
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with cancer biomarker validation
5.2.4.2 Shortage of skilled professionals
5.3 PRICING ANALYSIS
5.3.1 PRICING MODEL ANALYSIS
TABLE 6 INDICATIVE PRICING FOR CANCER BIOMARKER PRODUCTS (2023)
TABLE 7 AVERAGE SELLING PRICE OF CANCER BIOMARKER PRODUCTS, BY REGION
5.4 PATENT ANALYSIS
5.4.1 PATENT ANALYSIS OF CANCER BIOMARKERS MARKET
FIGURE 26 PATENT ANALYSIS FOR CANCER BIOMARKERS (JANUARY 2014-DECEMBER 2023)
5.5 VALUE CHAIN ANALYSIS
FIGURE 27 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET
FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 PORTER'S FIVE FORCES ANALYSIS
TABLE 8 CANCER BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 INTRODUCTION
5.9.2 CANCER BIOMARKERS QUALIFICATION IN US
5.9.3 CANCER BIOMARKERS QUALIFICATION IN EU
FIGURE 30 CANCER BIOMARKERS MARKET: EMA QUALIFICATION PROCEDURE
5.9.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN EU AND US
5.9.5 EMA APPROVALS
5.9.6 FDA APPROVALS
5.10 TRADE ANALYSIS
5.11 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
5.12 TECHNOLOGY ANALYSIS
5.13 KEY TECHNOLOGIES
5.13.1 POLYMERASE CHAIN REACTION
5.13.2 NEXT-GENERATION SEQUENCING
5.14 COMPLEMENTARY TECHNOLOGIES
5.14.1 IN SITU HYBRIDIZATION
5.15 ADJACENT TECHNOLOGIES
5.15.1 IMMUNOHISTOCHEMISTRY
5.16 KEY CONFERENCES & EVENTS IN 2024-2025
TABLE 11 CANCER BIOMARKERS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
5.17.1 REVENUE SHIFT & REVENUE POCKETS FOR CANCER BIOMARKERS MARKET
FIGURE 31 REVENUE SHIFT FOR CANCER BIOMARKERS MARKET
5.18 KEY STAKEHOLDERS & BUYING CRITERIA
5.18.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
5.18.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
TABLE 13 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
5.19 CASE STUDY ANALYSIS
5.19.1 CASE STUDY: CASE OF OVARIAN CANCER TO ILLUSTRATE BEST PRACTICE IN MACHINE LEARNING AND SHAPLEY ANALYSIS
5.20 INVESTMENT & FUNDING SCENARIO
TABLE 14 US: CANCER BIOMARKERS FUNDING BY VARIOUS INSTITUTES/CENTERS, 2021-2024
6 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
6.1 INTRODUCTION
TABLE 15 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022-2029 (USD MILLION)
6.2 OMICS TECHNOLOGIES
TABLE 16 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 17 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
6.2.1 PROTEOMICS
TABLE 18 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 19 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022-2029 (USD MILLION)
6.2.1.1 Immunoassays
6.2.1.1.1 Facilitate diagnosis of cancer at early stage
TABLE 20 IMMUNOASSAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
6.2.1.2 Mass spectrometry
6.2.1.2.1 High specificity of mass spectroscopy to drive adoption
TABLE 21 MASS SPECTROMETRY MARKET, BY REGION, 2022-2029 (USD MILLION)
6.2.1.3 2D gel electrophoresis
6.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment
TABLE 22 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2022-2029 (USD MILLION)
6.2.1.4 Protein microarrays
6.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth
TABLE 23 PROTEIN MICROARRAYS MARKET, BY REGION, 2022-2029 (USD MILLION)
6.2.1.5 Other proteomic technologies
TABLE 24 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2022-2029 (USD MILLION)
6.2.2 GENOMICS
TABLE 25 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 26 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022-2029 (USD MILLION)
6.2.2.1 Next-generation sequencing
6.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth
TABLE 27 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022-2029 (USD MILLION)
6.2.2.2 Polymerase chain reaction
6.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market
